 View printer-friendly version |
| << Back |
| Circulation Publishes Results From RUTHERFORD Study Which Showed AMG 145 Significantly Reduced LDL Cholesterol In Patients With Heterozygous Familial Hypercholesterolemia |
HeFH is one of the most common genetic disorders, affecting at least one out of every 500 people worldwide. HeFH causes severe elevations in total cholesterol and LDL-C, leading to the premature development of cardiovascular disease and early cardiovascular morbidity and mortality. In the RUTHERFORD trial, treatment with AMG 145 every four weeks (Q4W) resulted in a significant LDL-C decrease versus placebo in HeFH patients on lipid-lowering therapy (statins with or without ezetimibe). At week 12, LDL-C reduction, measured by preparative ultracentrifugation, was 43 percent and 55 percent with AMG 145 350 mg and 420 mg, respectively, compared to a 1 percent increase with placebo (p<0.001 for both dose groups). At week 12, treatment with AMG 145 350 mg and 420 mg Q4W resulted in 70 percent and 89 percent of patients reaching LDL-C levels of <100 mg/dL and 44 percent and 65 percent achieving <70 mg/dL, respectively, compared to 2 percent and 0 percent of placebo subjects, respectively. Favorable reductions in total cholesterol, non-HDL-C, Lp(a) and ApoB were consistent with the reductions in LDL-C. "Despite existing therapies and maintaining a healthy lifestyle, patients with heterozygous familial hypercholesterolemia are prematurely at risk for serious cardiovascular disease due to the difficulty in reducing their LDL-C levels," said The most common adverse events (AEs) for AMG 145 in this trial were nasopharyngitis, injection-site reaction and headache. This study is one of four Phase 2 studies of AMG 145 being presented at the American Heart Association Scientific Sessions 2012. RUTHERFORD Study Design Webcast Information About AMG 145 About Amgen Forward-Looking Statements No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the CONTACT: (Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO) SOURCE |
